Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER trial

Tolaney, SM; Goel, S; Appiah, AK; Huynh, T; Chen, Y; Andr&#233;, F

Author(s): Tolaney, SM; Goel, S; Appiah, AK; Huynh, T; Chen, Y; André, F;
Details: Publication Year 2023-11,Volume 19,Issue #35,Page 2341-2348
Journal Title: Future Oncology
Publication Type: Commentary
Abstract: WHAT IS THIS SUMMARY ABOUT? This article summarizes the results of a study called monarcHER. The study included participants with a certain type of aggressive breast cancer called HR+, HER2+ advanced breast cancer (ABC) that had their disease worsen or return after multiple previous therapies. This summary intends to help you understand the impact of a non-chemotherapy treatment called abemaciclib in people with HR+, HER2+ ABC. When the study was planned, HER2-targeted therapy (ie trastuzumab) was standard treatment and was typically combined with chemotherapy and endocrine therapy (ie fulvestrant). However drug resistance can develop when HER2+ targeted therapy is used for a long time, making it less effective and allowing cancer to grow or spread to other parts of the body. When this happens, few chemotherapy-free options are available. Because of the chemotherapy side effects, this is not desirable. There is an urgent need to develop new, effective, safe, and tolerable treatment options for patients with HR+, HER2+ ABC. The monarcHER study compared the effects of abemaciclib plus trastuzumab with or without fulvestrant compared to the standard of care treatment. WHAT WERE THE RESULTS? Participants were randomly assigned to 1 of 3 groups: Group A (abemaciclib, trastuzumab and fulvestrant), Group B (abemaciclib and trastuzumab), or Group C (trastuzumab and standard of care chemotherapy). The study compared the length of time patients took study treatments without worsening or dying from their breast cancer. This is called the progression free survival (PFS). Participants in Group A had a longer median PFS than those in groups B and C (8.3 months, 5.7 months and 5.7 months respectively). There was no notable difference in PFS between participants in Groups B and C. Additionally, the study looked at the side effects with each treatment group. The most common side effect which is considered severe or lifethreatening was neutropenia, defined as decreased white blood cell levels. Neutropenia may lead to an increased risk of getting infections. However, the percentage of patients experiencing neutropenia was similar in all groups A, B and C (27%, 22% and 26%, respectively). Patients in groups A (79%) and B (78%) who received abemaciclib experienced similar rates of diarrhea. WHAT DO THE RESULTS MEAN? The data from the monarcHER study suggest that the combination of abemaciclib, trastuzumab, and fulvestrant may offer a chemotherapy-free option for patients with HR+, HER2+ ABC who have experienced worsening of disease despite multiple prior therapies.
Keywords: Female; Humans; *Breast Neoplasms; Fulvestrant/therapeutic use; Trastuzumab/therapeutic use; Receptor, ErbB-2; *Neutropenia/chemically induced; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Randomized Controlled Trials as Topic; Her2+; Hr+; Lay Summary; abemaciclib; advanced breast cancer; monarcHER; plain language summary
Department(s): Medical Oncology; Laboratory Research
Publisher's Version: https://doi.org/10.2217/fon-2023-0078
Open Access at Publisher's Site: https://doi.org/10.2217/fon-2023-0078
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-01-04 02:56:45

Last Modified: 2024-01-04 02:57:34